9-position Substituted Patents (Class 514/180)
-
Publication number: 20140377332Abstract: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.Type: ApplicationFiled: November 21, 2013Publication date: December 25, 2014Inventors: Florian N. Ludwig, Stephen D. Pacetti, Syed F.A. Hossainy, Dariush Davalian
-
Publication number: 20140370072Abstract: Provided herein is a prohealing piezoelectric coating and the method of making and using the same.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: Syed Faiyaz Ahmed Hossainy, Mikael Trollsas, Lothar Walter Kleiner
-
Publication number: 20140370097Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.Type: ApplicationFiled: June 20, 2014Publication date: December 18, 2014Inventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
-
Publication number: 20140364836Abstract: The present invention provides compositions containing (i) a pharmaceutically active agent selected from a group consisting of an arylcycloalkyamine of a derivative, analogue or pharmaceutically active salt thereof, and (ii) a biocompatible polymer or a combination of biocompatible polymers. The compositions or medicaments containing these compositions may be used for the prevention and/or treatment of inner ear diseases, e.g. tinnitus.Type: ApplicationFiled: June 27, 2014Publication date: December 11, 2014Inventor: Thomas MEYER
-
Publication number: 20140364404Abstract: The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Inventors: Robert L. Cleek, Paul D. Drumheller, Theresa A. Holland
-
Publication number: 20140363498Abstract: Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.Type: ApplicationFiled: August 27, 2014Publication date: December 11, 2014Inventors: Amarpreet S. Sawhney, William H. Ransone, II
-
Patent number: 8906893Abstract: The present invention relates to substances, to electroluminescent device comprising these substances, and to the use thereof.Type: GrantFiled: November 17, 2011Date of Patent: December 9, 2014Assignee: Merck Patent GmbHInventors: Rémi Manouk Anémian, Aurélie Ludemann, Thomas Eberle, Sigurd Hoeger, Eva Maria Reis, Vanessa Bobbe
-
Publication number: 20140356437Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: August 18, 2014Publication date: December 4, 2014Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20140357609Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.Type: ApplicationFiled: August 19, 2014Publication date: December 4, 2014Inventors: Jeffrey L. Edelman, Kelly M. Harrison
-
Patent number: 8895056Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.Type: GrantFiled: December 21, 2012Date of Patent: November 25, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventors: Stephen D. Pacetti, Paul M. Consigny, Ronald W. Heil, Jr., Florian Niklas Ludwig, Dariush Davalian, Li Zhao, Irina Astafieva, Jinping Wan, Fozan El-Nounou, Katsuyuki Murase, Syed F. A. Hossainy, Rachel Bright, Jeffrey Ellis
-
Patent number: 8895069Abstract: The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.Type: GrantFiled: December 15, 2011Date of Patent: November 25, 2014Assignee: Postech Academy-Industry FoundationInventors: Sei Kwang Hahn, Choun-Ki Joo, Yoon Keun Kim, Seung Kew Yoon, Eun Ju Oh, Ki Su Kim, Hyemin Kim, Kitae Park, Jeong-A Yang, Jun-Sub Choi, You Me Tae, Wonhee Hur
-
Publication number: 20140336161Abstract: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.Type: ApplicationFiled: July 24, 2014Publication date: November 13, 2014Inventors: Arturo Angel, Gordon Dow
-
Publication number: 20140336162Abstract: This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot.Type: ApplicationFiled: July 28, 2014Publication date: November 13, 2014Inventors: William F. McKay, John Myers Zanella, Christopher M. Hobot
-
Publication number: 20140336164Abstract: Biodegradable non-ophthalmic implants include one or more agents dispersed within a biodegradable polymer component. The implants release the agents from the biodegradable polymer component to a target site of a patient as the implant degrades. The agents provided in the implants can be therapeutic agents or diagnostic agents and are useful in medical treatments of non-ocular regions of a patient.Type: ApplicationFiled: July 23, 2014Publication date: November 13, 2014Inventors: Steven Pal, Mitchell Brin
-
Publication number: 20140328912Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: ApplicationFiled: July 11, 2014Publication date: November 6, 2014Inventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
-
Publication number: 20140328926Abstract: The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses.Type: ApplicationFiled: July 16, 2014Publication date: November 6, 2014Inventors: David M. Gravett, George Y. Daniloff, Pingren He
-
Publication number: 20140328929Abstract: Results from two randomized trials have shown that oral beclomethasone dipropionate (BDP) is effective for treatment of acute gastrointestinal graft-versus-host disease (GVHD). Here, we report results of a double-blind, randomized placebo-controlled phase II study designed to test the hypothesis that acute GVHD could be prevented by administration of oral BDP, beginning before hematopoietic cell transplantation (HCT) and continuing until day 75 after HCT. Study drug (BDP or placebo) was administered as 1 mg immediate-release formulation plus 1 mg delayed-release formulation orally four times daily. According to the primary endpoint, systemic glucocorticoid treatment for GVHD was given to 60 of the 92 participants (65%) in the BDP arm, versus 31 of 46 participants (67%) in the placebo arm. The secondary efficacy endpoints showed no statistically significant differences between the two arms.Type: ApplicationFiled: November 30, 2012Publication date: November 6, 2014Inventors: George B. McDonald, Paul Martin, Christopher Schaber
-
Publication number: 20140328917Abstract: An organic compound nano-powder comprising a granular organic compound with an average particle diameter of 500 nm or less and a 90%-diameter of less than 1500 nm and a carbohydrate compound comprising at least any one of a sugar and a sugar alcohol and with amount of 0.3 times or more by mass relative to amount of the organic compound, a method for producing the same, and a suspension having the organic compound dispersed in a liquid dispersion medium in which the organic compound is insoluble or poorly soluble.Type: ApplicationFiled: May 11, 2013Publication date: November 6, 2014Inventors: Takahiro Tada, Kazuhiro Kagami, Shiro Yokota
-
Publication number: 20140322327Abstract: A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive agent, and at least one support selected from synthetic polymers, bio compounds and natural polymers. Also, methods for the manufacture of the system and methods of using it.Type: ApplicationFiled: November 15, 2012Publication date: October 30, 2014Applicant: UPM-KYMMENE CORPORATIONInventors: Antti Laukkanen, Ruzica Kolakovic, Leena Peltonen, Timo Laaksonen, Jouni Hirvonen, Heikki Lyytikainen, Harri Jukarainen, Prijo Kortesuo
-
Publication number: 20140314815Abstract: The present invention is drawn to adhesive solid gel-forming formulations, methods of drug delivery, and solidified gel layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a gelling agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein at least one non-volatile solvent is flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified gel layer after at least a portion of the volatile solvent system is evaporated. The solidified gel layer is can be removed by peeling or washing.Type: ApplicationFiled: January 22, 2014Publication date: October 23, 2014Applicant: Nuvo Research Inc.Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Patent number: 8865698Abstract: Provided herein are methods for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal, which comprises administering to said mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.Type: GrantFiled: July 16, 2013Date of Patent: October 21, 2014Assignee: Array BioPharma Inc.Inventors: Julia Haas, Steven W. Andrews, Yutong Jiang, Gan Zhang
-
Publication number: 20140303131Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Stephen PERRETT, Fredric Jay COHEN, Gopi VENKATESH
-
Publication number: 20140294922Abstract: It is described the use of betamethasone as antibacterial agent.Type: ApplicationFiled: December 1, 2011Publication date: October 2, 2014Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.p.A.Inventor: Aleardo Koverech
-
Publication number: 20140296128Abstract: The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns methods of inhibiting the growth of a tumor by administering a cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK and/or STAT3 inhibition and anti-tumor activity.Type: ApplicationFiled: April 7, 2014Publication date: October 2, 2014Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: SAID M. SEBTI, RICHARD JOVE
-
Publication number: 20140287051Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.Type: ApplicationFiled: June 3, 2014Publication date: September 25, 2014Applicant: APTALIS PHARMATECH, INC.Inventors: Stephen PERRETT, Fredric Jay COHEN, Gopi VENKATESH
-
Publication number: 20140287053Abstract: Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant.Type: ApplicationFiled: March 21, 2014Publication date: September 25, 2014Applicant: Eupraxia Pharmaceuticals USA LLCInventors: James A. Helliwell, Amanda M. Malone, Thomas J. Smith, Marc M. Baum
-
Publication number: 20140256696Abstract: The present invention describes steroid conjugates. These single drug entities are formed by connecting two or more steroids via a linker. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual steroid drugs.Type: ApplicationFiled: March 6, 2014Publication date: September 11, 2014Applicant: Allergan, Inc.Inventors: Santosh C. Sinha, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
-
Publication number: 20140255311Abstract: Disclosed are compositions and synthesis methods that pertain to biocompatible polymeric capsules capable of undergoing backbone degradation and cargo release upon exposure to biologically relevant concentrations of hydrogen peroxide (50-100 ?M of H2O2). In the invention, bio-responsive polyester bearing boronic ester triggers groups that degrade upon exposure to low concentrations of H2O2. The degradation is induced by transformation of a boronic ester to a phenol, which undergoes a quinone methide rearrangement to break down the polyester backbone.Type: ApplicationFiled: March 6, 2014Publication date: September 11, 2014Applicant: The Regents of the University of CaliforniaInventors: Adah Almutairi, Carolina De Gracia Lux
-
Publication number: 20140256695Abstract: Systems and method are disclosed for forming a biocompatible cross-linked polymer having an interpenetrating polymer network (IPN) by cross-linking a heteropolysaccharide to form a single cross-linked material; and performing one or more additional cross-linkings on the single cross-linked material to form a multiple cross-linked material, wherein the multiple cross-linked material has one or more IPN regions resisting biodegradation in a human body than the single cross-linked material and one or more single cross-linked extensions radiating out from the IPN, wherein the combination of the IPN and the extension provide biodegradation resistance, soft touch feeling, and ease of insertion into the human body.Type: ApplicationFiled: November 11, 2012Publication date: September 11, 2014Inventors: Phi Nguyen, Loc Phan, Bao Tran, Thuan Nguyen
-
Patent number: 8822438Abstract: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17?-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3?-acetoxy-17-(3-pyridyl)androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17?-hydroxylase/C17,20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.Type: GrantFiled: February 24, 2011Date of Patent: September 2, 2014Assignee: Janssen Oncology, Inc.Inventors: Alan H. Auerbach, Arie S. Belldegrum
-
Publication number: 20140242097Abstract: A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent.Type: ApplicationFiled: October 11, 2012Publication date: August 28, 2014Applicant: THE ROYAL VETERINARY COLLEGEInventors: Liam Good, Kantaraja Chindera, Valentina Gburcik
-
Publication number: 20140234225Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: ApplicationFiled: February 17, 2014Publication date: August 21, 2014Applicant: Alkermes Pharma Ireland LimitedInventors: Christian F. Wertz, Niels P. Ryde
-
Patent number: 8809307Abstract: The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.Type: GrantFiled: November 2, 2011Date of Patent: August 19, 2014Assignee: Dow Pharmaceutical Sciences, Inc.Inventors: Arturo Angel, Gordon Dow
-
Patent number: 8802128Abstract: Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.Type: GrantFiled: July 21, 2006Date of Patent: August 12, 2014Assignee: Allergan, Inc.Inventors: Michael R. Robinson, Scott M. Whitcup
-
Publication number: 20140219929Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: Foamix Ltd.Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
-
Publication number: 20140219923Abstract: A special class of drug-depot forming triblock copolymers which are very suitable for the loading, containment and releasing of sensitive drugs such as proteins from biodegradable, injectable drug depots. How to visualize these depots for various imaging related purposes is described. A composition comprising a tri-block copolymer according to formula 1 B-A-B (1), wherein A stands for a linear poly-(ethylene glycol) block and wherein B stands for wherein B stands for a poly(lactide-co-?-caprolactone) block, wherein the hydroxyl end-groups of the tri-block copolymer are at least partially acylated with an optionally substituted acyl having 2 to 12 C-atoms, C-atoms of the substituents included; an active ingredient, preferably a pharmaceutically active ingredient and a solvent, wherein the block ratio of the tri-block copolymer, which ratio is defined as the ratio between the sum of the average molecular weight of the B-blocks and the sum of the average molecular weight of the A-block ranges from 1.4 to 3.5.Type: ApplicationFiled: April 2, 2012Publication date: August 7, 2014Applicant: INGELL TECHNOLOGIES HOLDING B.V.Inventors: Peter Bruin, Audrey Petit, Mike De Leeuw, Martin Piest, Ronald Meijboom
-
Publication number: 20140221904Abstract: An implant for a living body is designed so that the drug release level can be adjusted to make it possible to perform treatment corresponding to the severity of disease state and the effectiveness of the drug on each individual. The implant includes a drug, and is inserted into a target part of a living body to effect sustained release of the drug, the implant including a photoactive agent that accelerates the release of the drug when irradiated with laser light. The implant is inserted into a living body, and laser light is appropriately applied to the implant to adjust the release level of the drug released into the living body. An eye disease or the like is treated using the above method.Type: ApplicationFiled: January 13, 2014Publication date: August 7, 2014Inventor: Masatoshi MURATA
-
Publication number: 20140213562Abstract: Methods relating to local injections of corticosteroids are provided. More specifically intralesional injections of corticosteroids and preferably Triamcinolone and its derivatives are suitable to produce medicaments to be injected in the subcutaneous fat at deep levels to provoke cosmetic lipoatrophy of small fat deposits on the face and body.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Inventor: Doris Hexsel
-
Publication number: 20140213564Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.Type: ApplicationFiled: July 12, 2013Publication date: July 31, 2014Inventors: Bhushan HARDAS, Donna Dalton, Petra Scheppler, Anja Hensche, Peter Boderke
-
Publication number: 20140206614Abstract: Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect.Type: ApplicationFiled: March 20, 2014Publication date: July 24, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Wouter E. Roorda, Stephen D. Pacetti
-
Publication number: 20140199291Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 17, 2014Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Publication number: 20140194400Abstract: The present invention relates to a nasel formulation comprising as its active ingredient an intranasal corticosteroid, and also to a method for prophylaxis or treatment of seasonal or perennial allergic and non-allergic rhinitis and rhinoconjunctivitis.Type: ApplicationFiled: May 24, 2012Publication date: July 10, 2014Applicant: Meda Pharma GmbH & Co., KgInventors: Annegret Hildebrand-Cyrener, Joachim Maus, Ullrich Munzel, Hans Tritschler, Mario Weingart
-
Publication number: 20140193475Abstract: The present invention provides an implantable article comprising an amorphous terpolymer and a semi-crystalline polymer. The amorphous terpolymer can be admixed with the semi-crystalline polymer or form a block copolymer with the semi-crystalline polymer.Type: ApplicationFiled: March 10, 2014Publication date: July 10, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Mikael Trollsas, Michael Ngo, Florencia Lim
-
Patent number: 8771729Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.Type: GrantFiled: October 1, 2010Date of Patent: July 8, 2014Assignee: Aptalis Pharmatech, Inc.Inventors: Stephen Perrett, Fredric Jay Cohen, Gopi Venkatesh
-
Publication number: 20140186278Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.Type: ApplicationFiled: September 19, 2013Publication date: July 3, 2014Inventor: Patrick Franke
-
Publication number: 20140186279Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: CAMURUS ABInventors: Fredrik JOABSSON, Margareta LINDEN, Krister THURESSON, Fredrik TIBERG
-
Publication number: 20140186417Abstract: An aliphatic polyester polymer for stent coating is described.Type: ApplicationFiled: February 20, 2014Publication date: July 3, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: O. Mikael Trollsas, Lothar W. Kleiner, Syed F.A. Hossainy
-
Patent number: 8765725Abstract: The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).Type: GrantFiled: January 7, 2013Date of Patent: July 1, 2014Assignee: Aciex Therapeutics, Inc.Inventors: Thomas Cavanagh, Shikha P. Barman
-
Publication number: 20140179653Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.Type: ApplicationFiled: October 11, 2013Publication date: June 26, 2014Applicants: APR APPLIED PHARMA RESEARCH SA, LABTEC GESELLSCHAFT FUR TECHNOLOGISCHE FORSCHUNG UND ENTWICKLUNG MBHInventors: Christian Leichs, Armin Breitenbach, Ingo Lehrke, Paolo Galfetti
-
Publication number: 20140148426Abstract: The present invention provides a method for treating psoriasis, by spraying onto the skin with psoriasis daily for at least 4 weeks a pharmaceutical composition containing an effective amount of clobetasol propionate. A preferred pharmaceutical composition containing clobetasol propionate, ethyl alcohol, isopropyl myristate, and anionic surfactant.Type: ApplicationFiled: January 17, 2014Publication date: May 29, 2014Applicants: Dermalogix Partners, Inc., Dow Pharmaceutical SciencesInventors: Gordon J. Dow, Daniel M. Stewart